Compare · DOX vs IQV
DOX vs IQV
Side-by-side comparison of Amdocs Limited (DOX) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- DOX operates in Technology, while IQV operates in Health Care - the two are in different parts of the market.
- IQV is the larger of the two at $44.09B, about 7.0x DOX ($6.30B).
- Over the past year, DOX is down 28.3% and IQV is up 53.7% - IQV leads by 82.0 points.
- IQV has been more active in the news (6 items in the past 4 weeks vs 1 for DOX).
- IQV has more recent analyst coverage (25 ratings vs 8 for DOX).
- Company
- Amdocs Limited
- IQVIA Holdings Inc.
- Price
- $58.24+0.69%
- $271.72-1.21%
- Market cap
- $6.30B
- $44.09B
- 1M return
- -6.49%
- +3.88%
- 1Y return
- -28.28%
- +53.71%
- Industry
- EDP Services
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 1
- 6
- Recent ratings
- 8
- 25
Amdocs Limited
Amdocs Limited, through its subsidiaries, provides software and services to the communications, cable and satellite, entertainment, and media industry service providers worldwide. The company offers a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support and operations, such as end-to-end systems integration, managed, testing, cloud, digital business operations, and consulting services that addresses service providers business imperatives, including consumer experience and monetization, media and digital services, enterprise and connected society, open cloud networks, new domains and disruptions, and services and hybrid operations. It also provides revenue guard services designed to detect and resolve revenue leakage, fraud, and cyber fraud; and the BriteBill, a multi-channel bill presentment platform. In addition, the company offers advertising and media services for media publishers, TV networks, video streaming providers, advertising agencies, and service providers. Amdocs Limited was founded in 1988 and is headquartered in Chesterfield, Missouri.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest DOX
- Amdocs CEO Shimie Hortig and CFO Tal Rozenfeld to Speak at the Goldman Sachs Communacopia + Technology Conference and Citi's 2026 Global TMT Conference in September
- Telefónica Chile and Amdocs Establish Strategic Multi-Year Agreement to Accelerate Modernization and Business Agility in Chile
- SEC Form 6-K filed by Amdocs Limited
- Amendment: SEC Form SCHEDULE 13G/A filed by Amdocs Limited
- SEC Form 6-K filed by Amdocs Limited
- Cielo Selects Amdocs to Bring Intelligent Connectivity to Its Entire Brazilian Payment Terminal Network
- Optimum Transforms Customer Bill Experience with AI-Enhanced Platform Powered by Amdocs aOS Cognitive Core
- Lumen Extends Multi-Cloud Strategy with Amdocs, Modernizing Enterprise Service Orchestration
- PLDT Home Selects Amdocs to Modernize Core Business Platform, Advancing Cloud-Ready Transformation
- Sunrise Extends its Strategic Collaboration with Amdocs, Advancing its CRM Evolution with aOS
Latest IQV
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- IQVIA Announces Offering of Senior Notes
- Officer Berkshire James G. exercised 5,381 shares at a strike of $131.82, sold $697,228 worth of shares (2,668 units at $261.33) and returned $709,558 worth of shares to the company (2,713 units at $261.54) (SEC Form 4)
- IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
- IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
- IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
- IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
- Officer Staub W Richard sold $1,279,740 worth of shares (5,500 units at $232.68), decreasing direct ownership by 29% to 13,312 units (SEC Form 4)